Research programme: autoimmune, inflammation and metabolic disease therapeutics - Harbor BioSciences

Drug Profile

Research programme: autoimmune, inflammation and metabolic disease therapeutics - Harbor BioSciences

Alternative Names: HE 3177; HE 3413

Latest Information Update: 27 May 2010

Price : $50

At a glance

  • Originator Hollis-Eden Pharmaceuticals
  • Developer Harbor Therapeutics
  • Class Androstenes; Hormonal steroids; Small molecules
  • Mechanism of Action NF-kappa B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Autoimmune disorders; Inflammation; Metabolic disorders

Most Recent Events

  • 27 May 2010 Preclinical development is ongoing in the USA
  • 06 Oct 2008 Preclinical development is ongoing
  • 12 Sep 2007 Preclinical trials in Inflammation in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top